Previous Close | 1.66 |
Open | 3.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 3.00 - 11.00 |
52 Week Range | 0.70 - 70.44 |
Volume | |
Avg. Volume | 53 |
Market Cap | N/A |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.14 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BURLINGTON, Mass., September 04, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern t
Designed in Virginia and commericalised by Johnson & Johnson, Lifenet Health’s bone allograft is aims to help surgeons expedite procedures.